S-8 S-8 EX-FILING FEES 0000873303 Sarepta Therapeutics, Inc. N/A Fees to be Paid Fees to be Paid 0000873303 2025-08-05 2025-08-05 0000873303 1 2025-08-05 2025-08-05 0000873303 2 2025-08-05 2025-08-05 iso4217:USD xbrli:pure xbrli:shares

Calculation of Filing Fee Tables

S-8

Sarepta Therapeutics, Inc.

Table 1: Newly Registered Securities

Security Type

Security Class Title

Fee Calculation Rule

Amount Registered

Proposed Maximum Offering Price Per Unit

Maximum Aggregate Offering Price

Fee Rate

Amount of Registration Fee

1 Equity Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan, as amended-Common Stock, par value $0.0001 per share Other 4,300,000 $ 16.01 $ 68,843,000.00 0.0001531 $ 10,539.87
2 Equity Sarepta Therapeutics, Inc. Amended and Restated 2013 Employee Stock Purchase Plan, as amended-Common Stock, par value $0.0001 per share Other 300,000 $ 16.01 $ 4,803,000.00 0.0001531 $ 735.34

Total Offering Amounts:

$ 73,646,000.00

$ 11,275.21

Total Fee Offsets:

$ 0.00

Net Fee Due:

$ 11,275.21

Offering Note

1

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this Registration Statement on Form S-8 (the "Registration Statement") shall also cover shares of the Registrant's common stock that become issuable under the Plans to prevent dilution as a result of any stock dividend, stock split, recapitalization or similar transaction. (2) Represents 4,300,000 shares of common stock reserved for future issuance under the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan, as amended. (3) Estimated solely for the purpose of determining the registration fee pursuant to Rule 457(c) and 457(h) under the Securities Act, the "proposed maximum offering price per share" is calculated based on the average of the high and low prices for the Registrant's common stock as reported on the Nasdaq Global Select Market on August 1, 2025.

2

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this Registration Statement on Form S-8 (the "Registration Statement") shall also cover shares of the Registrant's common stock that become issuable under the Plans to prevent dilution as a result of any stock dividend, stock split, recapitalization or similar transaction. (3) Estimated solely for the purpose of determining the registration fee pursuant to Rule 457(c) and 457(h) under the Securities Act, the "proposed maximum offering price per share" is calculated based on the average of the high and low prices for the Registrant's common stock as reported on the Nasdaq Global Select Market on August 1, 2025. (4) Represents 300,000 shares of common stock reserved for future issuance under the Sarepta Therapeutics, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (as amended and restated on June 27, 2016), as amended.

Table 2: Fee Offset Claims and Sources ☑Not Applicable
Registrant or Filer Name Form or Filing Type File Number Initial Filing Date Filing Date Fee Offset Claimed Security Type Associated with Fee Offset Claimed Security Title Associated with Fee Offset Claimed Unsold Securities Associated with Fee Offset Claimed Unsold Aggregate Offering Amount Associated with Fee Offset Claimed Fee Paid with Fee Offset Source
Rule 457(p)
Fee Offset Claims N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Fee Offset Sources N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A